Current Dengue Virus Vaccine Developments and Future Directions
Viruses · 2025
DOI: 10.3390/v17020212 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, 2025. Verfasst von Govindaraj Anumanthan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Immunology, University of Florida, Gainesville, FL 32611, USA. Hauptthemen laut MEDLINE: Dengue Vaccines, Dengue, Dengue Virus, Vaccine Development. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Florida Infectious Disease and Immunology Departmental Fund.
Abstract (Originalsprache)
Dengue fever (DF), a leading arboviral disease globally, is caused by the Dengue virus (DENV) and represents a significant public health concern, with an estimated 390 million cases reported annually. Due to the complexity of the various dengue variants and the severity of the disease, vaccination emerges as the essential strategy for combating this widespread infectious disease. The absence of specific antiviral medications underscores the critical need for developing a Dengue vaccine. This review aims to present the current status and future prospects of Dengue vaccine development. Further, this review elaborates on the various strategies employed in vaccine development, including attenuated, inactivated, subunit, and viral vector vaccines. Each approach is evaluated based on its immunogenicity, safety, and efficacy, drawing on data from preclinical and clinical studies to highlight the strengths and limitations of each candidate vaccine. The current study sheds light on future directions and research priorities in developing Dengue vaccines. In conclusion, the development of a Dengue vaccine holds significant potential for reducing the global burden of DF. However, challenges remain in terms of vaccine safety, efficacy, delivery, and availability. Overcoming these challenges, coupled with advancements in vaccine technology, could lead to better control and prevention of Dengue, thereby enhancing public health and quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases and Immunology, University of Florida, Gainesville, FL 32611, USA.
ORCID-Profile: Bikash Sahay, Ayalew Mergia
Förderung
- University of Florida Infectious Disease and Immunology Departmental Fund
Zitieren
APA
Anumanthan, G., Sahay, B., & Mergia, A. (2025). Current Dengue Virus Vaccine Developments and Future Directions. Viruses. https://doi.org/10.3390/v17020212
Vancouver
Anumanthan G, Sahay B, Mergia A. Current Dengue Virus Vaccine Developments and Future Directions. Viruses. 2025. doi:10.3390/v17020212
BibTeX
@article{Anumanthan2025,
author = {Anumanthan, Govindaraj and Sahay, Bikash and Mergia, Ayalew},
title = {Current Dengue Virus Vaccine Developments and Future Directions},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17020212}
}
EUVIMED